BioCentury
ARTICLE | Company News

Eddingpharm gets Chinese rights to ALX-0141 from Ablynx

October 19, 2013 12:29 AM UTC

Ablynx N.V. (Euronext:ABLX) granted Eddingpharm Inc. (Shanghai, China) exclusive rights in China and Taiwan to develop and commercialize ALX-0141, which has completed a Phase I trial to treat bone-loss related disorders. Ablynx will receive EUR 2 million ($2.7 million) up front and is eligible for undisclosed milestones, plus tiered double-digit royalties. Eddingpharm will be responsible for clinical development, registration and commercialization in China. Ablynx will have rights to data generated by Eddingpharm. ALX-0141 is a nanobody against receptor activator of NF-kappa B ligand ( RANKL). ...